CA2656285A1 - Processes for the synthesis of o-desmethylvenlafaxine - Google Patents
Processes for the synthesis of o-desmethylvenlafaxine Download PDFInfo
- Publication number
- CA2656285A1 CA2656285A1 CA002656285A CA2656285A CA2656285A1 CA 2656285 A1 CA2656285 A1 CA 2656285A1 CA 002656285 A CA002656285 A CA 002656285A CA 2656285 A CA2656285 A CA 2656285A CA 2656285 A1 CA2656285 A1 CA 2656285A1
- Authority
- CA
- Canada
- Prior art keywords
- desmethylvenlafaxine
- tridesmethyl venlafaxine
- venlafaxine
- mixture
- tridesmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 title description 6
- 238000003786 synthesis reaction Methods 0.000 title description 6
- BHCUWXACHAFFSK-UHFFFAOYSA-N 4-[2-amino-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound C1CCCCC1(O)C(CN)C1=CC=C(O)C=C1 BHCUWXACHAFFSK-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000000203 mixture Substances 0.000 claims description 42
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 27
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 26
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000012649 demethylating agent Substances 0.000 claims description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- -1 Marlotherm Substances 0.000 claims description 11
- 230000001335 demethylating effect Effects 0.000 claims description 11
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 239000012022 methylating agents Substances 0.000 claims description 7
- 238000006268 reductive amination reaction Methods 0.000 claims description 7
- XRZRPHKMCVBSLA-UHFFFAOYSA-M sodium;dodecane-1-thiolate Chemical group [Na+].CCCCCCCCCCCC[S-] XRZRPHKMCVBSLA-UHFFFAOYSA-M 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 230000001035 methylating effect Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 5
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 5
- 150000007944 thiolates Chemical class 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 229920002866 paraformaldehyde Polymers 0.000 claims description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 3
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 claims description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 claims description 2
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 claims description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims description 2
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229960004132 diethyl ether Drugs 0.000 claims description 2
- HRKQOINLCJTGBK-UHFFFAOYSA-N dihydroxidosulfur Chemical compound OSO HRKQOINLCJTGBK-UHFFFAOYSA-N 0.000 claims description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 2
- WVJOGYWFVNTSAU-UHFFFAOYSA-N dimethylol ethylene urea Chemical compound OCN1CCN(CO)C1=O WVJOGYWFVNTSAU-UHFFFAOYSA-N 0.000 claims description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229910052976 metal sulfide Inorganic materials 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 150000004681 metal hydrides Chemical class 0.000 claims 1
- 229910000000 metal hydroxide Inorganic materials 0.000 claims 1
- 150000004692 metal hydroxides Chemical class 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 17
- 229960004688 venlafaxine Drugs 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000004576 sand Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 230000017858 demethylation Effects 0.000 description 5
- 238000010520 demethylation reaction Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MOHIYTLRUDZQDP-UHFFFAOYSA-N 2-cyclohexyl-2-phenylpropanenitrile Chemical compound C=1C=CC=CC=1C(C#N)(C)C1CCCCC1 MOHIYTLRUDZQDP-UHFFFAOYSA-N 0.000 description 1
- NVAOLENBKNECGF-UHFFFAOYSA-N 2-phenylpropanenitrile Chemical compound N#CC(C)C1=CC=CC=C1 NVAOLENBKNECGF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910013698 LiNH2 Inorganic materials 0.000 description 1
- SUQHIQRIIBKNOR-UHFFFAOYSA-N N,N-didesmethylvenlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN)C1(O)CCCCC1 SUQHIQRIIBKNOR-UHFFFAOYSA-N 0.000 description 1
- 229910018954 NaNH2 Inorganic materials 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- ONIOAEVPMYCHKX-UHFFFAOYSA-N carbonic acid;zinc Chemical compound [Zn].OC(O)=O ONIOAEVPMYCHKX-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- LEDMRZGFZIAGGB-UHFFFAOYSA-L strontium carbonate Chemical compound [Sr+2].[O-]C([O-])=O LEDMRZGFZIAGGB-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
The present invention describes processes for the preparation of O-desmethylvenlafaxine and tridesmethylvenlafaxine, which may be used as an intermediate in preparing O-desmethylvenlafaxine.
Description
PROCESSES FOR THE SYNTHESIS OF O-DESMETHYLVENLAFAXINE
CROSS REFERENCE TO RELATED APPLICATIONS
[1] The present application claims the benefit of the following United States Provisional Patent Application Nos.: 60/833,616, filed July 26, 2006;
60/837,879, filed August 14, 2006; 60/849,216, filed October 3, 2006;
60/843,998, filed September 11, 2006; 60/849,255, filed October 3, 2006; 60/906,639, filed March 12, 2007; and 60/906,879, filed March 13, 2007. The contents of these applications are incorporated herein by reference.
FIELD OF THE INVENTION
CROSS REFERENCE TO RELATED APPLICATIONS
[1] The present application claims the benefit of the following United States Provisional Patent Application Nos.: 60/833,616, filed July 26, 2006;
60/837,879, filed August 14, 2006; 60/849,216, filed October 3, 2006;
60/843,998, filed September 11, 2006; 60/849,255, filed October 3, 2006; 60/906,639, filed March 12, 2007; and 60/906,879, filed March 13, 2007. The contents of these applications are incorporated herein by reference.
FIELD OF THE INVENTION
[2] The invention encompasses a process for the synthesis of O-desmethy.lvenlafaxine and a novel intermediate, tridesmethyl venlafaxine.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[3] Venlafaxine, (f)-1-[2-(Dimethylamino)-1-(4-ethyoxyphenyl) ethyl]
cyclo-hexanol is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors. Venlafaxine has the following chemical formula, Formula I:
H3C~
OH
H3C-O ~
Formula I
cyclo-hexanol is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors. Venlafaxine has the following chemical formula, Formula I:
H3C~
OH
H3C-O ~
Formula I
[4] O-desmethylvenlafaxine, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, is a major metabolite of venlafaxine and has been reported to inhibit norepinephrine and serotonin uptake. See Klamerus, K. J.
et al., "Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite," J. Clin. Pharmacal. 32:716-724 (1992). 0-desmethylvenlafaxine has the following chemical formula, Formula II:
et al., "Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite," J. Clin. Pharmacal. 32:716-724 (1992). 0-desmethylvenlafaxine has the following chemical formula, Formula II:
N,,\
OH
OH
C=teWzsNdz MoI. Wt: 263.3B
Formula II
[5] Processes for the synthesis of 0-desmethylvenlafaxine, comprising a step of demethylation of the phenol group of venlafaxine, are described in U.S. patent No. 7,026,508 and 6,689,912, and in U.S. publication No. 2005/0197392, which are incorporated herein by reference.
OH
OH
C=teWzsNdz MoI. Wt: 263.3B
Formula II
[5] Processes for the synthesis of 0-desmethylvenlafaxine, comprising a step of demethylation of the phenol group of venlafaxine, are described in U.S. patent No. 7,026,508 and 6,689,912, and in U.S. publication No. 2005/0197392, which are incorporated herein by reference.
[6] The synthesis disclosed in the above references is performed according to the following scheme:
0 4.1fv1 e UtVi,e OIVIe, , : .:
. , . ,;..; . ~
~ ~ H0 R<eduction :, . HO ...;r- .
C.N
MBt GmBsC DD IN1t O Me O'H
Meth.y.lation I J D'erneth:y.lation I~
H O /C H3 ----=. HO oCH 3 arnine N phen:ol N 3 `CH
YenlaFaidne VIFJ L ODV
"MBC" refers to methyl benzyl cyanide, "CIVIBC" refers to cyclohexyl methylbenzyl cyanide, "DDMV" refers to didesmethyl venlafaxine, and "ODV" refers to 0-desmethylvenlafaxine.
0 4.1fv1 e UtVi,e OIVIe, , : .:
. , . ,;..; . ~
~ ~ H0 R<eduction :, . HO ...;r- .
C.N
MBt GmBsC DD IN1t O Me O'H
Meth.y.lation I J D'erneth:y.lation I~
H O /C H3 ----=. HO oCH 3 arnine N phen:ol N 3 `CH
YenlaFaidne VIFJ L ODV
"MBC" refers to methyl benzyl cyanide, "CIVIBC" refers to cyclohexyl methylbenzyl cyanide, "DDMV" refers to didesmethyl venlafaxine, and "ODV" refers to 0-desmethylvenlafaxine.
[7] However, the processes disclosed in the above US patents and US
patent applications all remain problematic when applied to industrial scale production.
The process in US Patent No. 7,026,508 uses L-selectride, a compound which is very problematic when scaling up the process for industrial application. Further, the process disclosed in US Application Publication No. 2005/0197392 uses lithiumdiphenyl phosphine, a compound which handling and use in industrial scale processes is extremely dangerous. Also, the process disclosed in US Patent No 6,689,912 uses methanol as a solvent, which use is problematic when traces of methanol remain and in subsequent process steps when high temperatures are applied.
patent applications all remain problematic when applied to industrial scale production.
The process in US Patent No. 7,026,508 uses L-selectride, a compound which is very problematic when scaling up the process for industrial application. Further, the process disclosed in US Application Publication No. 2005/0197392 uses lithiumdiphenyl phosphine, a compound which handling and use in industrial scale processes is extremely dangerous. Also, the process disclosed in US Patent No 6,689,912 uses methanol as a solvent, which use is problematic when traces of methanol remain and in subsequent process steps when high temperatures are applied.
[8] Therefore, there is a need in the art for a new synthetic route for obtaining O-desmethylvenlafaxine, using a precursor of venlafaxine to directly obtain 0-desmethylvenlafaxine.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[9] In one embodiment, the invention encompasses tridesmethyl venlafaxine.
[10] In another embodiment, the invention encompasses a process for preparing tridesmethyl venlafaxine comprising demethylating didesmethylvenlafaxine to obtain tridesmethylvenlafaxine. The process of demethylating didesmethylvenlafaxine preferably comprises: combining didesmethylvenlafaxine, a solvent, and a sulfide containing demethylating agent to form a mixture, heating the mixture, and optionally recovering tridesmethyl venlafaxine from the mixture.
[11] In another embodiment, the present invention provides a process for preparing O-desmethylvenlafaxine comprising demethylating didesmethylvenlafaxine to obtain tridesmethyl venlafaxine, and converting said tridesmethyl venlafaxine to O-desmethylvenlafaxine.:
[12] In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine comprising reductive amination of tridesmethylvenlafaxine to obtain 0-desmethylvenlafaxine. The process of reductive amination of tridesmethylvenlafaxine preferably comprises: combining a solution of tridesmethyl venlafaxine and a formaldehyde source with a reducing agent, preferably sodium borohydride, sodium triacetoxy borohydride, or sodium cyanoborohydride, to obtain a reaction mixture, and recovering the 0-desmethylvenlafaxine from the reaction mixture.
[13] - In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine comprising selectively N,N methylating tridesmethylvenlafaxine to obtain O-desmethylvenlafaxine. The process of selectively N,N methylating tridesmethylvenlafaxine preferably comprises:
combining tridesmethyl venlafaxine, an organic solvent, and a methylating agent to form a mixture, and recovering the 0-desmethylvenlafaxine from the mixture.
DETAILED DESCRIPTION OF THE ITNVENTION
combining tridesmethyl venlafaxine, an organic solvent, and a methylating agent to form a mixture, and recovering the 0-desmethylvenlafaxine from the mixture.
DETAILED DESCRIPTION OF THE ITNVENTION
[14] The embodiment of the invention encompasses a new synthetic route for obtaining 0-desmethylvenlafaxine directly from a venlafaxine intermediate.
[15] In a process according to the invention, the methoxy group of didesmethyl venlafaxine ("DDMV"), its chemical name being 1-[2-amino-l-(4-methoxyphenyl)ethyl]cyclohexanol, is demethylated to form the intermediate tridesmethyl venlafaxine ("TDMV"), its chemical name being 4-[2-amino-l-(1-hydroxycyclohexyl)ethyl]phenol. The intermediate TDMV is then subjected to reductive amination or selective N,N methylation to produce 0-desmethylvenlafaxine ("ODV"), as described in the following scheme:
OMe OH OH
.- . .`:~ . ._t . .`
. ~. . . ,,~ . : :..i H Q HO HO ,,CHa.
.._ ;
.. ,, ~ , .
NHZ
Q~pMU TDMV
OO;V ;
wherein "TDMV" refers to the novel intermediate tridesmethyl venlafaxine.
OMe OH OH
.- . .`:~ . ._t . .`
. ~. . . ,,~ . : :..i H Q HO HO ,,CHa.
.._ ;
.. ,, ~ , .
NHZ
Q~pMU TDMV
OO;V ;
wherein "TDMV" refers to the novel intermediate tridesmethyl venlafaxine.
[16] As used herein the term "room temperature" means the ambient temperature of an typical laboratory, which is usually about that of Standard Temperature and Pressure (STP).
[17] As used herein the term "increased pressure" refers to a pressure above 1 atmosphere as is commonly understood by one of skill in the art. Conversely, as used herein, the term "reduced pressure" means a pressure of below 1 atmosphere as commonly understood by one of skill in the art.
[18] As used herein, the term " substantially pure" means a compound of very high purity as is understood by one of skill in the art such as for example a purity of at least 95% by HPLC area percent.
[19] As used herein, an "isolated" compound means the compound has been separated from the reaction mixture in which it was formed.
[20] In one embodiment, the present invention provides tridesmethyl venlafaxine, chemically named 4-[2-amino-l-(1-hydroxycyclohexyl)ethyl] phenol and having the following Formula III:
OH
OH
tridesmethyl venlafaxine Formula III
OH
OH
tridesmethyl venlafaxine Formula III
[21] The tridesmethyl venlafaxine or salts thereof as in the present invention may have a purity of 75% by HPLC area percent or higher. Preferably, tridesmethyl venlafaxine or its salt is substantially pure, more preferably at least 95%
pure by HI'LC area percent, most preferably at least 98% pure by HPLC area percent.
pure by HI'LC area percent, most preferably at least 98% pure by HPLC area percent.
[22] In one embodiment tridesmethyl venlafaxine is prepared by demethylating didesmethyl venlafaxine to obtain tridesmethylvenlafaxine.
Demethylation of disdesmethylvenlafaxine may be carried out by reacting didesmethyl venlafaxine with a sulfide containing demethylating agent. This reaction comprises maintaining a mixture of didesmethylvenlafaxine and the sulfide containing demethylating agent at an elevated temperature for a sufficient time to form tridesmethyl venlafaxine.
Demethylation of disdesmethylvenlafaxine may be carried out by reacting didesmethyl venlafaxine with a sulfide containing demethylating agent. This reaction comprises maintaining a mixture of didesmethylvenlafaxine and the sulfide containing demethylating agent at an elevated temperature for a sufficient time to form tridesmethyl venlafaxine.
[23] As used herein, the term "elevated temperature" means a temperature greater than about 50 C, but less than a temperature at which about 10% or more of either the reactants or the product degrades over the course of the reaction.
Preferably, the elevated temperature at which the demethylating reaction of the process of the present invention is carried out is from about 100 C to about 300 C, more preferably from about 120 C to about 250 C, even more preferably from about 140 C to about 210 C, at atmospheric pressure. Alternatively, the demethylating reaction of didesmethylvenlafaxine in the presence of a sulfide containing demethylating agent may be carried out a correspondingly lower temperature under increased pressure.
Preferably, the elevated temperature at which the demethylating reaction of the process of the present invention is carried out is from about 100 C to about 300 C, more preferably from about 120 C to about 250 C, even more preferably from about 140 C to about 210 C, at atmospheric pressure. Alternatively, the demethylating reaction of didesmethylvenlafaxine in the presence of a sulfide containing demethylating agent may be carried out a correspondingly lower temperature under increased pressure.
[24] Preferably, tridesmethyl venlafaxine may be prepared by a process comprising combining didesmethylvenlafaxine, a solvent, and a sulfide containing demethylating agent to form a mixture, heating the mixture, and optionally recovering tridesmethyl venlafaxine from the mixture.
[25] A suitable solvent for use in the above process may be a high boiling point solvent, particularly when the process is carried out at atmospheric pressure.
The term "high boiling point solvent" is used and understood by one of ordinary skill in the art and refers to a solvent having a boiling point higher than about 100 C.
Preferably, the high boiling point solvent is selected from the group consisting of:
toluene, dimethylformamide ("DMF"), dimethylsulfoxide ("DMSO '), N-methyl-2-pyridone, N-methyl-2-pyrrolidone (NMP), 1-methyl-2-pyrolidinone, dimethylacetamide ("DMA"), polyethylene glycol, Marlotherm, silicon oil, N,N'-dimethylpropyleneurea ("DMPU"), dimethylolethyleneurea ("DMEU"), Hexamethylphosphoramide ("H1bII'A"), diethylformamide ("DEF"), diethyleneamine ("DEA"), morpholine, sulfolane, phenylether and mixtures thereof. More preferably, the high boiling point solvent is polyethylene glycol,lVMP or DMA.
The term "high boiling point solvent" is used and understood by one of ordinary skill in the art and refers to a solvent having a boiling point higher than about 100 C.
Preferably, the high boiling point solvent is selected from the group consisting of:
toluene, dimethylformamide ("DMF"), dimethylsulfoxide ("DMSO '), N-methyl-2-pyridone, N-methyl-2-pyrrolidone (NMP), 1-methyl-2-pyrolidinone, dimethylacetamide ("DMA"), polyethylene glycol, Marlotherm, silicon oil, N,N'-dimethylpropyleneurea ("DMPU"), dimethylolethyleneurea ("DMEU"), Hexamethylphosphoramide ("H1bII'A"), diethylformamide ("DEF"), diethyleneamine ("DEA"), morpholine, sulfolane, phenylether and mixtures thereof. More preferably, the high boiling point solvent is polyethylene glycol,lVMP or DMA.
[26] Preferably, the didesmethyl venlafaxine starting material is didesmethyl venlafaxine free base, which can be obtained by any method known to the skilled artisan, such as described in U.S. patent No. 7,026,508 and U.S.
patent No.
6,689,912, herein incorporated by reference, or by conversion of the commercially available salt to the free base form. Such conversion may comprise dissolving a commercially available salt of didesmethylvenlafaxine, such as a hydrochloride salt or acetate salt thereof, in an organic solution, preferably a CI.4 alcohol such as methanol, and adding a base such as for example sodium hydroxide to the solution. The didesmethylvanlafaxine free base may then be recovered, for example, by evaporation of the solvent. Altematively, a salt of didesmethylvenlafaxine may be used as starting material without prior conversion to the free base. The free base of didesmethyl venlafaxine may then be prepared in situ by the addition of a base.
patent No.
6,689,912, herein incorporated by reference, or by conversion of the commercially available salt to the free base form. Such conversion may comprise dissolving a commercially available salt of didesmethylvenlafaxine, such as a hydrochloride salt or acetate salt thereof, in an organic solution, preferably a CI.4 alcohol such as methanol, and adding a base such as for example sodium hydroxide to the solution. The didesmethylvanlafaxine free base may then be recovered, for example, by evaporation of the solvent. Altematively, a salt of didesmethylvenlafaxine may be used as starting material without prior conversion to the free base. The free base of didesmethyl venlafaxine may then be prepared in situ by the addition of a base.
[27] The sulfide containing demethylating agent is selected from metal sulfides, having either a valence of -1 or -2, thiolates and thiols.
Preferably, the demethylating agent is a mercaptan or a salt thereof, a salt of a thioalcohol, or sodium sulfide. A preferred thiolate is a high molecular weight thiolate or arene thiolate.
More preferably, the sulfide containing demethylating agent is sodium dodecanethiolate or thiophenol. The sodium dodecanethiolate can be obtained by any method known to the skilled artisan, such as combining sodium methoxide, methanol and dodecanethiol.
Preferably, the demethylating agent is a mercaptan or a salt thereof, a salt of a thioalcohol, or sodium sulfide. A preferred thiolate is a high molecular weight thiolate or arene thiolate.
More preferably, the sulfide containing demethylating agent is sodium dodecanethiolate or thiophenol. The sodium dodecanethiolate can be obtained by any method known to the skilled artisan, such as combining sodium methoxide, methanol and dodecanethiol.
[28] Whenever thiophenol is used, a base catalyst is preferably employed in the reaction mixture. Preferably, the base catalyst is a metal carbonate, hydride, hydroxide, amide or oxide. More preferably the base catalyst is selected from the group consisting of K2C03, Li2CO3, Na2CO3, CS2CO3, MgCO3, CaCO3, BaCO3, SrCO3, ZnCO3, NaHCO3, KHCO3, LiOH, NaOH, CsOH, LiH, NaH, KH, CaH2, LiNH2, NaNH2, and tBuOK, most preferably potassium carbonate.
[29] Preferably, the mixture is heated to a temperature of about 100 C to about 300 C, preferably of about 140 C to about 210 C, preferably of about 155 C to about 190 C, at atmospheric pressure. The reaction mixture may be heated to a temperature of about 50 C to about 200 C, preferably about 80 C, whenever the demethylating reaction is carried out under pressure (increased pressure).
Under pressure, the reaction may be carried out an increased pressure of more than 1 atmosphere, preferably at a pressure between about 1 bar to about 10 bar. The mixture is heated for a sufficient period of time to obtain the tridesmethylvenlafaxine, preferably for a period of about 1 hour to about 12 hours, more preferably of about 2 hours to about 6 hours, even more preferably for a period of about 2.5 hours to about 5.5 hours.
Under pressure, the reaction may be carried out an increased pressure of more than 1 atmosphere, preferably at a pressure between about 1 bar to about 10 bar. The mixture is heated for a sufficient period of time to obtain the tridesmethylvenlafaxine, preferably for a period of about 1 hour to about 12 hours, more preferably of about 2 hours to about 6 hours, even more preferably for a period of about 2.5 hours to about 5.5 hours.
[30] The tridesmethyl venlafaxine may be recovered from the mixture by any method known to the skilled artisan. In one embodiment, recovery of tridesmethylvenlafaxine from the mixture comprises the steps of cooling the mixture;
slurrying the obtained cooled mixture, preferably by adding silica; filtering and washing the slurry with a C1-C4 alcohol, preferably isopropanol; suspending the slurry in a CI-C4 alcohol, preferably isopropanol, and adjusting the pH to pH 8;
filtering the suspension; and evaporating the solvent from the filtrate.
slurrying the obtained cooled mixture, preferably by adding silica; filtering and washing the slurry with a C1-C4 alcohol, preferably isopropanol; suspending the slurry in a CI-C4 alcohol, preferably isopropanol, and adjusting the pH to pH 8;
filtering the suspension; and evaporating the solvent from the filtrate.
[31] In order to yield an even purer product, TDMV recovered as described above may then be slurried in water at ambient temperature for about 10 minutes to about 24 hours, preferably about 2 hours, preferably followed by removal of the water and preferably washing of the obtained product with water. TDMV so obtained is then preferably filtered and dried to yield crystalline TDMV. Optionally, the slurry may be cooled to about 0 C.
[32] In another embodiment, the present invention provides a process for preparing O-desmethylvenlafaxine comprising demethylating didesmethylvenlafaxine to obtain tridesmethyl venlafaxine, and converting said tridesmethyl venlafaxine to 0-desmethylvenlafaxine.
[33] In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine or a salt thereof comprising reductive amination of tridesmethylvenlafaxine to obtain 0-desmethylvenlafaxine. The process of reductive amination of tridesmethylvenlafaxine preferably comprises: combining a solution of tridesmethyl venlafaxine and a formaldehyde source with a reducing agent to obtain a reaction mixture and recovering the 0-desmethylvenlafaxine from the reaction mixture.
[34] The tridesmethyl venlafaxine starting material may be provided in a solution with a suitable solvent, preferably an organic solvent such as C1.4 alcohol, preferably methanol or isopropanol, or a C1_6 carboxylic acid, preferably acetic acid or formic acid, or C6-C8 aromatic hydrocarbons, preferably toluene, or C3-CS
ketones, preferably acetone and mixtures thereof. Additional solvents that can be used are also N1VIP and DMF. Alternatively, the suitable solvent can be water.
ketones, preferably acetone and mixtures thereof. Additional solvents that can be used are also N1VIP and DMF. Alternatively, the suitable solvent can be water.
[35] Optionally, the process is performed under acidic conditions. If the solvent used is not already acidic, an inorganic acid, such as HCl, or organic acid is added, preferably a C1.6 carboxylic acid, more preferably formic acid or an acetic acid.
[36] The desired N,N-dimethylation of tridesmethylvenlafaxine may be carried out using an aldehyde, a preferred aldehyde being formaldehyde. Any source of formaldehyde can be used, such as gaseous formaldehyde, paraformaldehyde ("paraform"), a formalin solution, and trioxane to mention just a few of those known to one of ordinary skill in the art.
[37] A suitable reducing agent is selected from the group consisting of sodium borohydride, sodium triacetoxy borohydride, and sodium cyanoborohydride.
Prior to combining the reducing agent, the solution may be cooled to a temperature of less than about 10 C, preferably less than about 5 C, more preferably to a temperature between about 0 C and about 5 C.
Prior to combining the reducing agent, the solution may be cooled to a temperature of less than about 10 C, preferably less than about 5 C, more preferably to a temperature between about 0 C and about 5 C.
[38] The O-desmethylvenlafaxine may be recovered from the reaction mixture by any method known to the skilled artisan.
[39] In another embodiment, the present invention provides a process for preparing 0-desmethylvenlafaxine comprising selectively N,N methylating tridesmethylvenlafaxine to obtain 0-desmethylvenlafaxine. The process of selectively N,N methylating tridesmethylvenlafaxine preferably comprises:
combining tridesmethyl venlafaxine and a methylating agent, preferably with an organic solvent, to form a mixture, and recovering the 0-desmethylvenlafaxine from the mixture.
combining tridesmethyl venlafaxine and a methylating agent, preferably with an organic solvent, to form a mixture, and recovering the 0-desmethylvenlafaxine from the mixture.
[40] A preferred organic solvent is selected from the group consisting of dichloromethane, dimethylsulfoxide, acetonitrile, tetrahydrofuran, diethylether, and hexane.
[41] Optionally, the process is performed under basic conditions.
Preferably, the source for providing basic reaction conditions may be selected from the group consisting of butyllithium, triethylamine, and sodium hydride.
Preferably, the source for providing basic reaction conditions may be selected from the group consisting of butyllithium, triethylamine, and sodium hydride.
[42] A preferred methylating agent is selected from the group consisting of a methyl halide, preferably methyl iodide, and dimethylsulfate.
[43] The reaction may be carried out for a period of time sufficient to obtain 0-desmethylvenlafaxine. A "sufficient" amount of time depends in part on the desired extent of reaction and the reaction conditions, such as temperature.
One of ordinary skill in the art can easily monitor the reaction to determine when a sufficient amount of time has transpired. The preferred amount of time is generally about minutes to about 24 hours, preferably about 18 hours.
One of ordinary skill in the art can easily monitor the reaction to determine when a sufficient amount of time has transpired. The preferred amount of time is generally about minutes to about 24 hours, preferably about 18 hours.
[44] The 0-desmethylvenlafaxine may be recovered from the mixture by any method known to the skilled artisan.
[45] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the synthesis of the compound tridesmethyl venlafaxine and further its conversion to 0-desmethylvenlafaxine. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
Examnle 1: Determining the purit /y impurity profile of tridesmethyl venlafaxine and 0-desmethylvenlafaxine by HPLC.
HPLC
Colunin & Packing: Zorbax SB C-18 4.6*250mm Part No.28105-020 or equivalent column Column Temperature: 25 C
Buffer Add 4.Oml of trifluoroacetic acid and 7.Oml of triethylamine to 1 L of water adjust the pH to3.0 with triethylamine.
Eluent:
Reservoir A 30 1oAcetonitrile and 70% Buffer Reservoir B To a mixture of 700m1 Acetonitrile and 300m1 buffer add 1.6m1 of trifluoroacetic acid and 2.9m1 of triethylamine measure the pH it should be about 3.0 (correct the pH with triethylaxnine or trifluoroacetic acid if necessary).
Gradient Time Reservoir A Reservoir B
0 100% 0%
21 min 100% 0%
55 min 45% 55%
Equilibrium time: l Omin Flow Rate: 1.0 ml/min Detector: 230 nm Sample Volume: 10 l Diluent: Eluent A
Mobile phase composition and flow rate may. be varied in order to achieve the required system suitability.
Sample Preparation Weigh accurately about 10 mg of sample in a 20m1 amber volumetric flask.
Dissolve with eluent A.
Method Inject the sample solutioris into the chromatograph, continuing the chromatogram of sample up to the end of the gradient. Detern7ine the areas for each peak in each solution using a suitable integrator.
Calculation Impurity Profile Determination % impurity =area impurity in sample x 100 Total area Example 2: Preparation of tridesmethyl venlafaxine 1) Neutralization of Didesmethylvenlafaxine hydrochloride ("DD1VIVxHC1") [46] DDMVxHCI (5.73 g, 20 mmol) was dissolved in a minimum volume of methanol, and sodium hydroxide (0.88 g, 22 mmol) was added to form a mixture.
The mixture was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C.
2) Preparation of sodium dodecanethiolate [47] In another flask, sodium methoxide (1.43 g, 26 mmol) was dissolved in ml methanol, and dodecanethiol (6.5 ml, 27 mrnol) was added. The resulting solution was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C.
3) Demethylation [48] The DDMV free base produced in step 1) was taken in polyethylene glycol ("PEG") 400 (5 ml) and added to the flask containing sodium dodecanethiloate of step 2). Additional PEG 400 (3m1) was used to wash the flask of step 1).
The resulting mixture was heated at 190 C with a sand bath under nitrogen flow.
The internal temperature of the flask reached 155 C. The reaction was monitored by thin layer chromatography ("TLC") and determined to be complete after 2.5 hours.
Example 3: Preparation of tridesmethyl venlafaxine 1) Neutralization of Didesmethylvenlafaxine hydrochloride ("DDMVxHCI") [49] DDMVxHC1(30 g, 105 mmol) was dissolved in a minimum volume of methanol, and sodium hydroxide (6.24 g, 115 mmol) was added to form a mixture.
The mixture was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C. Traces of methanol were evaporated by adding toluene and evaporating it at reduced pressure at 100 C overnight.
2) Preparation of sodium dodecanethiolate [50] In another flask, sodium methoxide (8.1 g, 150 mmol) was dissolved in ml methanol, and dodecanethiol (32.8 ml, 136.6 mmol) was added. The resulting solution was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C. Traces of methanol were evaporated by adding toluene and evaporating it at reduced pressure at 100 C for two hours.
3) Demethylation [51] The DDMV free base produced in step 1) was taken in polyethylene glycol ("PEG") 400 (30 ml) and added to the flask containing sodium dodecanethiloate of step 2). Additional PEG 400 (3ml) was used to wash the flask of step 1). The resulting mixture was heated at 190 C with a sand bath under nitrogen flow. The internal temperature of the flask reached 190 C. The reaction was monitored by thin layer chromatography and deterrnined to be complete after 3 hours_ 4) Work Up [52] The reaction mixture was allowed to cool. When the temperature reached 110 C, toluene (100 ml) was added. When the temperature reached room temperature, silica (30 g) was added and the resulting slurry stirred for 1 hour. Then the silica was filtered. The filtrate was determined to contain dodecanethiol (and methyl dodecane thioether) by TLC analysis. The silica, which contained the product, was then suspended in isopropanol (100 mL) to forrn a slurry. The resulting slurry was stirred at 60 C for 1 hour. The slurry was then filtered and the filtrate was determined to contain ODV, DDMV, and an impurity. The silica was again suspended in isopropanol (100ml) and a solution of hydrochloric acid in isopropanol was added until pH=8. The silica was then filtered and the solvent from the filtrate was evaporated to recover pure TDMV, with a purity of 100% by HPLC area percent, yield 52%.
Examnle 4: Preparation of tridesmethyl venlafaxine [53] DDMVxHCI (2 g, 7 mmol), NaOMe (0.96g, 17.7 mmol), dodecanethiol (2.3 ml=1.84 g, 9 mmol) and DMA (4 ml) were mixed together and placed in rotovapor under reduced pressure in order to evaporate all traces of MeOH
formed during the contact of NaOMe with dodecanethiol and DDMV.HCI. The mixture was then heated in a sand bath at 180 C. (t;.=135 C). After 2.5 hours, a sample was analyzed by HPLC, containing 36% TDMV.
Example 5: Preparation of tridesmethyl venlafaxine [54] DDMVxHCI (1 g, 4 mmol), K2C03 (0.6g, 4.4 rnmol), thiophenol (0.8m1, 6 mmol) and NMP (4 ml) were charged in a 50 ml flask and heated in a sand bath. The temperature of the bath was kept at 210 C for 6 hours. HPLC analysis confirmed full consumption of DDMV. TDMV was obtained with a purity of 83.5%
by HPLC area percent.
Example 6: Preparation of tridesmethyl venlafaxine [55] DDMVxHC1 (10 g, 40 mmol), K2C03 (6g, 44 mmol), Thiophenol (8m1, 60 mmol) and NMP (40 ml) were charged in a 250 ml flask equipped with magnetic stirrer, condenser and nitrogen inlet, and heated in a sand bath. The temperature of the bath was kept at 210 C for 5.5 hours. HPLC analysis confirmed full consumption of DDMV. TDMV was obtained with a purity of 95% by HPLC
area percent.
Example 7: Prepartion of TDMV from DDIVIV:
EXAMPLES
Examnle 1: Determining the purit /y impurity profile of tridesmethyl venlafaxine and 0-desmethylvenlafaxine by HPLC.
HPLC
Colunin & Packing: Zorbax SB C-18 4.6*250mm Part No.28105-020 or equivalent column Column Temperature: 25 C
Buffer Add 4.Oml of trifluoroacetic acid and 7.Oml of triethylamine to 1 L of water adjust the pH to3.0 with triethylamine.
Eluent:
Reservoir A 30 1oAcetonitrile and 70% Buffer Reservoir B To a mixture of 700m1 Acetonitrile and 300m1 buffer add 1.6m1 of trifluoroacetic acid and 2.9m1 of triethylamine measure the pH it should be about 3.0 (correct the pH with triethylaxnine or trifluoroacetic acid if necessary).
Gradient Time Reservoir A Reservoir B
0 100% 0%
21 min 100% 0%
55 min 45% 55%
Equilibrium time: l Omin Flow Rate: 1.0 ml/min Detector: 230 nm Sample Volume: 10 l Diluent: Eluent A
Mobile phase composition and flow rate may. be varied in order to achieve the required system suitability.
Sample Preparation Weigh accurately about 10 mg of sample in a 20m1 amber volumetric flask.
Dissolve with eluent A.
Method Inject the sample solutioris into the chromatograph, continuing the chromatogram of sample up to the end of the gradient. Detern7ine the areas for each peak in each solution using a suitable integrator.
Calculation Impurity Profile Determination % impurity =area impurity in sample x 100 Total area Example 2: Preparation of tridesmethyl venlafaxine 1) Neutralization of Didesmethylvenlafaxine hydrochloride ("DD1VIVxHC1") [46] DDMVxHCI (5.73 g, 20 mmol) was dissolved in a minimum volume of methanol, and sodium hydroxide (0.88 g, 22 mmol) was added to form a mixture.
The mixture was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C.
2) Preparation of sodium dodecanethiolate [47] In another flask, sodium methoxide (1.43 g, 26 mmol) was dissolved in ml methanol, and dodecanethiol (6.5 ml, 27 mrnol) was added. The resulting solution was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C.
3) Demethylation [48] The DDMV free base produced in step 1) was taken in polyethylene glycol ("PEG") 400 (5 ml) and added to the flask containing sodium dodecanethiloate of step 2). Additional PEG 400 (3m1) was used to wash the flask of step 1).
The resulting mixture was heated at 190 C with a sand bath under nitrogen flow.
The internal temperature of the flask reached 155 C. The reaction was monitored by thin layer chromatography ("TLC") and determined to be complete after 2.5 hours.
Example 3: Preparation of tridesmethyl venlafaxine 1) Neutralization of Didesmethylvenlafaxine hydrochloride ("DDMVxHCI") [49] DDMVxHC1(30 g, 105 mmol) was dissolved in a minimum volume of methanol, and sodium hydroxide (6.24 g, 115 mmol) was added to form a mixture.
The mixture was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C. Traces of methanol were evaporated by adding toluene and evaporating it at reduced pressure at 100 C overnight.
2) Preparation of sodium dodecanethiolate [50] In another flask, sodium methoxide (8.1 g, 150 mmol) was dissolved in ml methanol, and dodecanethiol (32.8 ml, 136.6 mmol) was added. The resulting solution was stirred at room temperature for 15 minutes. The solvent was then evaporated under reduced pressure at 90 C. Traces of methanol were evaporated by adding toluene and evaporating it at reduced pressure at 100 C for two hours.
3) Demethylation [51] The DDMV free base produced in step 1) was taken in polyethylene glycol ("PEG") 400 (30 ml) and added to the flask containing sodium dodecanethiloate of step 2). Additional PEG 400 (3ml) was used to wash the flask of step 1). The resulting mixture was heated at 190 C with a sand bath under nitrogen flow. The internal temperature of the flask reached 190 C. The reaction was monitored by thin layer chromatography and deterrnined to be complete after 3 hours_ 4) Work Up [52] The reaction mixture was allowed to cool. When the temperature reached 110 C, toluene (100 ml) was added. When the temperature reached room temperature, silica (30 g) was added and the resulting slurry stirred for 1 hour. Then the silica was filtered. The filtrate was determined to contain dodecanethiol (and methyl dodecane thioether) by TLC analysis. The silica, which contained the product, was then suspended in isopropanol (100 mL) to forrn a slurry. The resulting slurry was stirred at 60 C for 1 hour. The slurry was then filtered and the filtrate was determined to contain ODV, DDMV, and an impurity. The silica was again suspended in isopropanol (100ml) and a solution of hydrochloric acid in isopropanol was added until pH=8. The silica was then filtered and the solvent from the filtrate was evaporated to recover pure TDMV, with a purity of 100% by HPLC area percent, yield 52%.
Examnle 4: Preparation of tridesmethyl venlafaxine [53] DDMVxHCI (2 g, 7 mmol), NaOMe (0.96g, 17.7 mmol), dodecanethiol (2.3 ml=1.84 g, 9 mmol) and DMA (4 ml) were mixed together and placed in rotovapor under reduced pressure in order to evaporate all traces of MeOH
formed during the contact of NaOMe with dodecanethiol and DDMV.HCI. The mixture was then heated in a sand bath at 180 C. (t;.=135 C). After 2.5 hours, a sample was analyzed by HPLC, containing 36% TDMV.
Example 5: Preparation of tridesmethyl venlafaxine [54] DDMVxHCI (1 g, 4 mmol), K2C03 (0.6g, 4.4 rnmol), thiophenol (0.8m1, 6 mmol) and NMP (4 ml) were charged in a 50 ml flask and heated in a sand bath. The temperature of the bath was kept at 210 C for 6 hours. HPLC analysis confirmed full consumption of DDMV. TDMV was obtained with a purity of 83.5%
by HPLC area percent.
Example 6: Preparation of tridesmethyl venlafaxine [55] DDMVxHC1 (10 g, 40 mmol), K2C03 (6g, 44 mmol), Thiophenol (8m1, 60 mmol) and NMP (40 ml) were charged in a 250 ml flask equipped with magnetic stirrer, condenser and nitrogen inlet, and heated in a sand bath. The temperature of the bath was kept at 210 C for 5.5 hours. HPLC analysis confirmed full consumption of DDMV. TDMV was obtained with a purity of 95% by HPLC
area percent.
Example 7: Prepartion of TDMV from DDIVIV:
[56] 1) Neutralization ofDDMVxHCI.
DDMVxHCI (10 g, 0.034 mol) was dissolved in MeOH(15 ml), and NaOMe (2.07 g, 0.038 mol) was added. The mixture was stirred at room temperature for 30 minutes, and the solvent evaporated under reduced pressure at 90 C.
2) Demethylation DDMV free base (prepared in stepl) was taken in NMP (15 ml) and Na2S (4.3g, 0.035 mol) was added to 250 ml flask equipped with mechanical stirrer, condenser and nitrogen inlet. The reaction mixture was heated in sand bath to 230 C and the reaction was monitored by HPLC.
Example 8: Preparation of TDMV under pressure [57] A 250 ml autoclave is charged with 5g DDMV base (0.020mol), 4.41 g thiophenol (0.040mo1, 2 eq) and solvent (10 ml) and catalytic amount of K2C03.
The reaction mixture is stirred from 40 C to 220 C and 1-10 bar pressure for 4h.
The mixture is then cooled to room temperature. At ambient temperature solvent (10 ml) and water (10 ml) are added and the product is recovered to obtain TDMV.
Example 9: Preparation of TDMV from DDMV:
DDMVxHCI (10 g, 0.034 mol) was dissolved in MeOH(15 ml), and NaOMe (2.07 g, 0.038 mol) was added. The mixture was stirred at room temperature for 30 minutes, and the solvent evaporated under reduced pressure at 90 C.
2) Demethylation DDMV free base (prepared in stepl) was taken in NMP (15 ml) and Na2S (4.3g, 0.035 mol) was added to 250 ml flask equipped with mechanical stirrer, condenser and nitrogen inlet. The reaction mixture was heated in sand bath to 230 C and the reaction was monitored by HPLC.
Example 8: Preparation of TDMV under pressure [57] A 250 ml autoclave is charged with 5g DDMV base (0.020mol), 4.41 g thiophenol (0.040mo1, 2 eq) and solvent (10 ml) and catalytic amount of K2C03.
The reaction mixture is stirred from 40 C to 220 C and 1-10 bar pressure for 4h.
The mixture is then cooled to room temperature. At ambient temperature solvent (10 ml) and water (10 ml) are added and the product is recovered to obtain TDMV.
Example 9: Preparation of TDMV from DDMV:
[58] DDMV.HCl (10 g, 35 mrnol), K2C03 (5.1g, 38.4 mmol), Thiophenol (6.2m1, 52.5 mmol) and NMP (20m1) were charged in a 100 ml flask equipped with mechanical stirrer, condenser and nitrogen inlet, and were heated in a sand bath. The temperature of the reaction mixture was about 125 CfIO C for 4 hours. The reaction mixture was cooled to 90 C and H20 (50 ml) was added dropwise inducing precipitation. The slurry was cooled to 25 C and stirred for about 80 minutes.
The solid was filtered, washed with H20 (20 ml) and left on filter over night and dried at 40 C under vacuum until constant weight to give white crystalline product (98.5%
area purity by HPLC). The compound so-obtained was slurried in water (50m1) at ambient temperature for 2 hours. The solid was filtered, washed with H20 (20 ml) and left on filter overnight and dried at 40 C under vacuum to give crystalline product.
Example 10: Prenaration of TDMV from DDMV in DMA:
The solid was filtered, washed with H20 (20 ml) and left on filter over night and dried at 40 C under vacuum until constant weight to give white crystalline product (98.5%
area purity by HPLC). The compound so-obtained was slurried in water (50m1) at ambient temperature for 2 hours. The solid was filtered, washed with H20 (20 ml) and left on filter overnight and dried at 40 C under vacuum to give crystalline product.
Example 10: Prenaration of TDMV from DDMV in DMA:
[59] DDMV.HCI (10 g, 35 mmol), K2C03 (5.1g, 38.4 mmol), Thiophenol (6.2ml, 52.5 mmol) and DMA (20m1) were charged in a 100 ml flask equipped with mechanical stirrer, condenser and nitrogen inlet, and heated in a sand bath.
The temperature of the reaction mixture was about 110 C=L 10 C for 3 hours. The reaction mixture was cooled to 90 C and H20 (50 ml) was added dropwise inducing precipitation. The slurry was cooled to 25 C and stirred for about 4 hours _The solid was filtered, washed with H20 (20 ml) and left on filter overnight (95% area purity by HPLC). The compound so-obtained was slurried in water (50m1) at ambient temperature for 2 hours, filtered, washed with .HZ0 (20 ml) dried at 40 C
under vacuum to give crystalline product.
Example 11: Preparation of TDMV from DDMV with Na2S in NMP:
The temperature of the reaction mixture was about 110 C=L 10 C for 3 hours. The reaction mixture was cooled to 90 C and H20 (50 ml) was added dropwise inducing precipitation. The slurry was cooled to 25 C and stirred for about 4 hours _The solid was filtered, washed with H20 (20 ml) and left on filter overnight (95% area purity by HPLC). The compound so-obtained was slurried in water (50m1) at ambient temperature for 2 hours, filtered, washed with .HZ0 (20 ml) dried at 40 C
under vacuum to give crystalline product.
Example 11: Preparation of TDMV from DDMV with Na2S in NMP:
[60] DDMV.HC1(81.36 g, 284 mmol), Na2S (40.0g, 313 mmol), mmol) and NMP (165m1) were charged in a 500 ml reactor equipped with mechanical stirrer, condenser dean stark and nitrogen inlet The reaction mixture was heated to 185 C.
The reaction mixture was stirred at 185 C for 8 hours. The reaction mixture was cooled to 90 C succinic acid (20 g 169 mmol)in H20 (500 ml) was added dropwise inducing precipitation. The slurry was cooled to 25 C and stirred overnight The solid was filtered, washed with H20 (2x80 ml) and dried overnight at 50 C under vacuum to get TDMV (96.91 % area purity by HPLC- yield 80%).
Example 12: Preparation of O-desmeth ly venlafaxine [61] TDMV (0.2 g, 0.85 mmol) was dissolved in methanol. Formalin solution (0.4 ml, 5 mmol) was added and the resulting solution was cooled in an ice bath. To the cold solution, NaBH4 (65 mg, 1.7 mmol) was added. After 15 min a sample was analyzed by HPLC, and determined to contain 85 % ODV by HPLC area percent.
Example 13: Preparation of 0-desmethylvenlafaxine [62] TDMV (0.2 g, 0.85 mmol) was dissolved in acetic acid (1 ml).
Formalin solution (1.5 ml, 17 mmol) was added to the solution and the solution was cooled in an ice bath. To the cold solution NaBH(OAc)3 (65 mg, 1.7 mmol) was added, forning a slurry that could not be stirred. Acetic acid (1 mL) was added to dilute the slurry. After 15 min, a sample was analyzed by HPLC and determined to contain 36 % ODV by HPLC area percent.
Example 14: Preparation of O-desmethylvenlafaxine [63] TDMV (0.2g, 0.85 mmol) was dissolved in dimethylsulfoxide (2.5 ml).
The resulting solution was cooled in an ice bath causing its solidification.
1.6 M butyl lithium solution in hexane (1.1 ml, 1.7 mmol) was added, and the temperature was allowed to rise to room temperature. Then methyl iodide (0.13 ml, 2.04 mmol) was added. After 30 minutes, HPLC analysis indicated the presence of ODV.
Exaxnple 15: Preparation of O-desmethylvenlafaxine [64] TDMV (0.5 g, 2.12 mmol) was suspended in CHZC12. Methyl iodide (0.26 ml, 4.3 mmol) and triethylamine (0.66 ml, 4.73 mmol) were added. The reaction mixture was stirred under nitrogen atmosphere at room temperature for 6 hours.
At this stage methyl iodide (0.5 ml) and NEt3 (1.2 ml) were added. The addition caused the temperature to rise. After 16 hours, HPLC analysis indicated the presence of ODV.
The reaction mixture was stirred at 185 C for 8 hours. The reaction mixture was cooled to 90 C succinic acid (20 g 169 mmol)in H20 (500 ml) was added dropwise inducing precipitation. The slurry was cooled to 25 C and stirred overnight The solid was filtered, washed with H20 (2x80 ml) and dried overnight at 50 C under vacuum to get TDMV (96.91 % area purity by HPLC- yield 80%).
Example 12: Preparation of O-desmeth ly venlafaxine [61] TDMV (0.2 g, 0.85 mmol) was dissolved in methanol. Formalin solution (0.4 ml, 5 mmol) was added and the resulting solution was cooled in an ice bath. To the cold solution, NaBH4 (65 mg, 1.7 mmol) was added. After 15 min a sample was analyzed by HPLC, and determined to contain 85 % ODV by HPLC area percent.
Example 13: Preparation of 0-desmethylvenlafaxine [62] TDMV (0.2 g, 0.85 mmol) was dissolved in acetic acid (1 ml).
Formalin solution (1.5 ml, 17 mmol) was added to the solution and the solution was cooled in an ice bath. To the cold solution NaBH(OAc)3 (65 mg, 1.7 mmol) was added, forning a slurry that could not be stirred. Acetic acid (1 mL) was added to dilute the slurry. After 15 min, a sample was analyzed by HPLC and determined to contain 36 % ODV by HPLC area percent.
Example 14: Preparation of O-desmethylvenlafaxine [63] TDMV (0.2g, 0.85 mmol) was dissolved in dimethylsulfoxide (2.5 ml).
The resulting solution was cooled in an ice bath causing its solidification.
1.6 M butyl lithium solution in hexane (1.1 ml, 1.7 mmol) was added, and the temperature was allowed to rise to room temperature. Then methyl iodide (0.13 ml, 2.04 mmol) was added. After 30 minutes, HPLC analysis indicated the presence of ODV.
Exaxnple 15: Preparation of O-desmethylvenlafaxine [64] TDMV (0.5 g, 2.12 mmol) was suspended in CHZC12. Methyl iodide (0.26 ml, 4.3 mmol) and triethylamine (0.66 ml, 4.73 mmol) were added. The reaction mixture was stirred under nitrogen atmosphere at room temperature for 6 hours.
At this stage methyl iodide (0.5 ml) and NEt3 (1.2 ml) were added. The addition caused the temperature to rise. After 16 hours, HPLC analysis indicated the presence of ODV.
Claims (42)
1. Tridesmethyl venlafaxine.
2. The tridesmethyl venlafaxine of claim 1, wherein the tridesmethyl venlafaxine is isolated.
3. The tridesmethyl venlafaxine of any of the preceding claims, wherein the tridesmethyl venlafaxine is substantially pure.
4. The tridesmethyl venlafaxine of any of the preceding claims, wherein the purity is about 75% by weight or greater.
5. The tridesmethyl venlafaxine of claim 4, wherein the purity is about 95% by weight or greater.
6. A process for preparing the tridesmethyl venlafaxine of any of the preceding claims comprising demethylating didesmethylvenlafaxine.
7. The process of claim 6, wherein demethylating comprises reacting didesmethylvenlafaxine with a sulfide containing demethylating agent.
8. The process of claim 7, wherein the reaction of didesmethylventalfaxine with the demethylating agent comprises maintaining a mixture of didesmethylvenlafaxine and the demethylating agent in a solvent at an elevated temperature for a sufficient time to form tridesmethyl venlafaxine.
9. The process of claim 8, further comprising: combining didesmethylvenlafaxine, a high boiling point solvent, and the demethylating agent to form a mixture, and heating the mixture to a temperature of from about 100°C to about 300°C.
10. The process of claim 9, wherein the temperature is from about 140°C
to about 210°C.
to about 210°C.
11. The process of claim 10, wherein the temperature is from about 155°C to about 190°C.
12. The process of any of claims 98 to 11, wherein the mixture is maintained at an elevated temperature for a period of about 1 hour to about 12 hours.
13. The process of any of claims 99 to 12, wherein the high boiling point solvent is selected from the group consisting of: toluene, dimethylformamide ("DMF"), dimethylsulfoxide ("DMSO"), N-methyl-2-pyridone, N-methyl-2-pyrrolidone (NMP), 1-methyl-2-pyrolidinone, dimethylacetamide ("DMA"), polyethylene glycol, Marlotherm, silicon oil, N,N'-dimethylpropyleneurea ("DMPU"), dimethylolethyleneurea ("DMEU"), hexamethylphosphoramide diethylformamide ("DEF"), diethyleneamine ("DEA"), morpholine, sulfolane, phenylether and mixtures thereof.
14. The process of claim 13, wherein the high boiling point solvent is polyethylene glycol, NMP or DMA.
15. The process of claim 8, wherein the mixture is heated to a temperature of about 50°C to about 200°C under a pressure of about 1 bar to about 10 bar.
16. The process of claim 15, wherein the temperature is about 80°C.
17. The process of any one of claims 7 to 16, wherein the sulfide containing demethylating agent is selected from metal sulfides, the sulfide having a valence of -1 or -2, thiolates and thiols.
18. The process of claim 17, wherein the demethylating agent is selected from a mercaptan, a salt of a thioalcohol, and sodium sulfide.
19. The process of claim 18, wherein the demethylating agent is a high molecular weight thiolate or arene thiolate or thiol.
20. The process of claim 19, wherein the demethylating agent is sodium dodecanethiolate or thiophenol.
21. The process of claim 20, wherein the demethylating agent is thiophenol, and further comprising adding a catalyst to the mixture.
22. The process of claim 21, wherein the catalyst is a base catalyst selected from the group consisting of metal carbonates, metal hydrides, metal hydroxides, metal amides, and metal oxides.
23. The process of claim 22, wherein the catalyst is potassium carbonate.
24. The process of any of claims 7-23, further comprising recovering tridesmethylvenlafaxine from the mixture.
25. A process for preparing O-desmethylvenlafaxine comprising reductive amination of the tridesmethyl venlafaxine ("TDMV") of any of claims 1 to 5 to produce O-desmethylvenlafaxine ("ODV").
26. The process of claim 25, comprising: combining a tridesmethyl venlafaxine and a formaldehyde source with a reducing agent to form O-desmethylvenlafaxine.
27. The process of claim 26, wherein the tridesmethyl venlafaxine is in a solution of a solvent selected from the group consisting of a C1-4 alcohol, a C1-6 carboxylic acid, a C6-C8 aromatic hydrocarbon, a C3-C5 ketone, NMP, DMF, and mixtures thereof.
28. The process of any of claims 2626 or 27, wherein the process is carried out under acidic conditions.
29. The process of claim 28, wherein the process is carried out in the presence of an organic acid.
30. The process of claim 29, wherein the organic acid is formic acid or acetic acid.
31. The process of any of claims 2626 to 30, wherein the source of formaldehyde is selected from the group consisting of gaseous formaldehyde, paraformaldehyde, fomalin solution, and trioxane.
32. The process of any of claims 26 to 31, wherein the reducing agent is selected from the group consisting of sodium borohydride, sodium triacetoxy borohydride, and sodium cyanoborohydride.
33. The process of any of claims 26 to 32, further comprising cooling the mixture of tridesmethyl venlafaxine and a formaldehyde source to a temperature of less than about 10°C, followed by combining the mixture with a reducing agent.
34. A process for preparing O-desmethylvenlafaxine by selectively N,N
methylating tridesmethylvenlafaxine comprising: combining tridesmethyl venlafaxine of any of claims 1 to 5 and a methylating agent to form O-desmethylvenlafaxine.
methylating tridesmethylvenlafaxine comprising: combining tridesmethyl venlafaxine of any of claims 1 to 5 and a methylating agent to form O-desmethylvenlafaxine.
35. The process of claim 34, wherein the tridesmethyl venlafaxine and the methylating agent are combined with an organic solvent selected from the group consisting of dichloromethane, dimethylsulfoxide, acetonitrile, tetrahydrofuran, diethylether, and hexane.
36. The process of any of claims 3434 or 35, wherein the process is carried out under basic conditions.
37. The process of claim 36, wherein the basic conditions are provided by a base selected from the group consisting of butyllithium, triethylamine, and sodium hydride.
38. The process of any of claims 3434 to 37, wherein the methylating agent is selected from the group consisting of a methyl halide, and dimethylsulfate.
39. A process for preparing O-desmethylvenlafaxine comprising demethylating didesmethylvenlafaxine to obtain tridesmethyl venlafaxine according to any of claims 6 to 24, and converting said tridesmethyl venlafaxine to O-desmethylvenlafaxine.
40. The process of claim 39, wherein the converting step comprises reductive amination of the tridesmethyl venlafaxine to form O-desmethylvenlafaxine according to any of claims 25 to 33.
41. The process of claim 39, wherein the converting step comprises selectively N,N methylating the tridesmethyl venlafaxine with a methylating agent to form O-desmethylvenlafaxine according to any of claims 34 to 38.
42. Use of tridesmethylvenlafaxine in a process for manufacturing O-desmethylvenlafaxine.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83361606P | 2006-07-26 | 2006-07-26 | |
US60/833,616 | 2006-07-26 | ||
US83787906P | 2006-08-14 | 2006-08-14 | |
US60/837,879 | 2006-08-14 | ||
US84399806P | 2006-09-11 | 2006-09-11 | |
US60/843,998 | 2006-09-11 | ||
US84925506P | 2006-10-03 | 2006-10-03 | |
US84921606P | 2006-10-03 | 2006-10-03 | |
US60/849,216 | 2006-10-03 | ||
US60/849,255 | 2006-10-03 | ||
US90663907P | 2007-03-12 | 2007-03-12 | |
US60/906,639 | 2007-03-12 | ||
US90687907P | 2007-03-13 | 2007-03-13 | |
US60/906,879 | 2007-03-13 | ||
PCT/US2007/017011 WO2008013995A2 (en) | 2006-07-26 | 2007-07-26 | Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2656285A1 true CA2656285A1 (en) | 2008-01-31 |
Family
ID=39750813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002656285A Abandoned CA2656285A1 (en) | 2006-07-26 | 2007-07-26 | Processes for the synthesis of o-desmethylvenlafaxine |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA2656285A1 (en) |
IL (1) | IL196269A0 (en) |
WO (1) | WO2008013995A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007016179A (en) | 2006-04-17 | 2008-03-11 | Teva Pharma | Polymorphic forms of tegaserod maleate. |
US20090069601A1 (en) * | 2006-07-26 | 2009-03-12 | Valerie Niddam-Hildesheim | Processes for the synthesis of O-desmethylvenlafaxine |
KR101409554B1 (en) | 2010-03-29 | 2014-06-19 | 플리바 흐르바츠카 디.오.오. | Crystal forms of o-desmethylvenlafaxine fumarate |
CZ303249B6 (en) | 2010-04-06 | 2012-06-20 | Zentiva, K.S. | Process for preparing 4-(2-(substituted)-1-(1-hydroxycyclohexyl)ethyl)phenols by O-demethylation of their methyl ethers using odor free aromatic thiols |
US8933123B2 (en) | 2010-10-08 | 2015-01-13 | Cadila Healthcare Limited | Polymorphic forms of O-desmethyl-venlafaxine succinate |
CN108752235B (en) * | 2018-06-19 | 2020-11-10 | 武汉普元药业有限责任公司 | Method for preparing drug intermediate by hydrotalcite material catalysis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197828B1 (en) * | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
DE60039132D1 (en) * | 1999-04-06 | 2008-07-17 | Sepracor Inc | O-desmethylvenlafaxine succinate |
UA80543C2 (en) * | 2001-12-04 | 2007-10-10 | Wyeth Corp | Method for the preparation of o-desmethylvenlafaxine |
TWI306092B (en) * | 2003-03-11 | 2009-02-11 | Wyeth Corp | Process for preparation of phenethylamine derivatives |
EP2007708A1 (en) * | 2006-04-17 | 2008-12-31 | Teva Pharmaceutical Industries Ltd | Substantially pure o-desmethylvenlafaxine and processes for preparing it |
-
2007
- 2007-07-26 WO PCT/US2007/017011 patent/WO2008013995A2/en active Application Filing
- 2007-07-26 CA CA002656285A patent/CA2656285A1/en not_active Abandoned
-
2008
- 2008-12-30 IL IL196269A patent/IL196269A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008013995A2 (en) | 2008-01-31 |
IL196269A0 (en) | 2009-11-18 |
WO2008013995A3 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7605290B2 (en) | Processes for the synthesis of O-desmethylvenlafaxine | |
CA2656285A1 (en) | Processes for the synthesis of o-desmethylvenlafaxine | |
US20080221356A1 (en) | Processes for the synthesis of O-desmethylvenlafaxine | |
US20070149813A1 (en) | Process for preparation of phenethylamine derivatives | |
CA2646368A1 (en) | Substantially pure o-desmethylvenlafaxine and processes for preparing it | |
EP3461552B1 (en) | Carbon dioxide absorbent and apparatus of separating and recovering carbon dioxide | |
WO2009073066A1 (en) | Processes for the synthesis of o-desmethylvenlafaxine | |
US20090137846A1 (en) | Processes for the synthesis of O-Desmethylvenlafaxine | |
WO2003101917A2 (en) | A process for the preparation of phenylcarbamates | |
AU2018260728A1 (en) | Process for the preparation of deuterated ethanol from D2 | |
EP2606030B1 (en) | Process for the preparation of tapentadol | |
AU2008315740A1 (en) | Process for preparing O-desmethylvenlafaxine | |
EP2349976B1 (en) | A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates | |
EP1937662B1 (en) | Process for the preparation of duloxetine | |
ITMI20100740A1 (en) | PREPARATION PROCESS OF CHLORIDATED RITODRINE | |
ES2553434T3 (en) | Process for the preparation of cinacalcet and intermediaries | |
MX2008004088A (en) | Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine | |
US8324429B2 (en) | Preparation method of rivastigmine, its intermediates and preparation method of the intermediates | |
EP2711354B1 (en) | Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates | |
CA2656166A1 (en) | Processes for the synthesis of o-desmethylvenlafaxine | |
EP1721887A1 (en) | Optically active 1-aryl-2-fluoro-substituted ethylamine and method for producing same | |
CN104326927A (en) | Preparation method of 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol sulfate | |
US6982354B2 (en) | Preparation of ketone containing cyclic compounds | |
JPWO2010013666A1 (en) | Method for producing carbamate compound | |
BRPI0702914A2 (en) | o-desmethylvenlafaxine synthesis processes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |